Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INAVAC immunobridging study in adolescents
NCT06282692Phase 3Recruiting
- Sponsor
- Dr. Soetomo General Hospital
- Start
- Jun 2023
- Primary completion
- May 2024
- Modality
- Split/Subunit Vaccines, Recombinant Protein Vaccines
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of salmonella typhi capsular polysaccharide vaccine in coronavirus disease 2019 (COVID-19), sponsored by Dr. Soetomo General Hospital. Primary endpoint: Vaccine Neutralizing Antibody Profile. Started Jun 2023; status: recruiting.
02
Drugs
salmonella typhi capsular polysaccharide vaccine
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT06282692.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06282692.